P. Westervelt

F. Gao, R. Vij, P. Westervelt, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?

R. Vij, P. Westervelt, J. Dipersio, 2016, Leukemia.

A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome

F. Gao, R. Vij, P. Westervelt, 2016, Leukemia & lymphoma.

Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

C. Bloomfield, R. Bejar, P. Greenberg, 2015 .

Cellular immune therapy for refractory cancers: novel therapeutic strategies.

P. Westervelt, D. Porter, P. Quesenberry, 2005, Experimental hematology.

High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma

W. Levy, P. Westervelt, R. Emmons, 2003, Bone Marrow Transplantation.

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

Andrew Homb, R. Vij, P. Westervelt, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Targeted Sequencing Informs the Evaluation of Normal Karyotype Cytopenic Patients for Low-Grade Myelodysplastic Syndrome

Christopher A. Miller, R. Wilson, R. Fulton, 2016, Leukemia.

Hematologic Recovery Following Pre-Transplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients

Ravi, F. Gao, P. Westervelt, 2016 .

Myeloid Growth FactorsPractice Guidelines in Oncology

J. Armitage, G. Lyman, P. Westervelt, 2011 .

NCCN Myeloid Growth Factors Clinical Practice Guidelines in Oncology

J. Armitage, G. Lyman, P. Westervelt, 2011 .

Pharmacokinetic Study of Infusional Valspodar

H. McLeod, P. Westervelt, P. Fracasso, 2002, Journal of clinical pharmacology.

Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial.

P. Westervelt, M. Horowitz, Stephanie J. Lee, 2016, JAMA oncology.

Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection.

F. Gao, R. Vij, P. Westervelt, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2016, Leukemia research.

Comprehensive Characterization of Cancer Driver Genes and Mutations

Steven J. M. Jones, Christopher A. Miller, Joshua M. Stuart, 2018, Cell.

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies

P. Westervelt, A. McBride, 2012, Journal of Hematology & Oncology.

Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Low-dose (550 cGy), single-exposure total body irradiation and cyclophosphamide: consistent, durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity.

R. Vij, P. Westervelt, J. Dipersio, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

An exploratory phase 2 study of investigational Aurora A kinase inhibitor alisertib (MLN8237) in acute myelogenous leukemia and myelodysplastic syndromes

P. Westervelt, P. Fenaux, H. Fingert, 2014, Leukemia research reports.

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020.

H. Rugo, G. Lyman, P. Westervelt, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Protective effect of CMV reactivation on relapse after allogeneic hematopoietic cell transplantation in AML patients is influenced by their conditioning regimen Blood Marrow

R. Vij, P. Westervelt, C. Abboud, 2014 .

Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10‐day decitabine regimen

F. Gao, J. Welch, R. Vij, 2017, Cancer medicine.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

C. Bloomfield, M. Millenson, H. Deeg, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.

R. Vij, P. Westervelt, J. Dipersio, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A bcr-3 isoform of RARα-PML potentiates the development of PML-RARα-driven acute promyelocytic leukemia

T. Ley, P. Pelicci, P. Westervelt, 1999 .

A bcr-3 isoform of RARalpha-PML potentiates the development of PML-RARalpha-driven acute promyelocytic leukemia.

T. Ley, P. Pelicci, P. Westervelt, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Identification of HIV1 determinants for T lymphoid cell line infection.

P. Westervelt, L. Ratner, D. B. Trowbridge, 1993, Virology.

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

R. Vij, P. Westervelt, G. Ramsingh, 2013, Leukemia.

The Role Of Early TP53 Mutations On The Evolution Of Therapy-Related AML

Christopher A. Miller, R. Wilson, R. Fulton, 2013 .

Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901.

K. Owzar, P. Westervelt, S. Farag, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML.

R. Vij, P. Westervelt, J. Dipersio, 2010 .

A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.

P. Westervelt, J. Dipersio, L. Gorelik, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia

R. Vij, P. Westervelt, J. Dipersio, 2014, American journal of hematology.

Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for sézary syndrome

P. Westervelt, L. Cornelius, R. Fields, 2019, Journal of Immunotherapy for Cancer.

A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes

R. Vij, S. Kulkarni, K. Trinkaus, 2021, Leukemia & lymphoma.

A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia

M. Konopleva, M. Andreeff, P. Westervelt, 2017, Blood Cancer Journal.

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

R. Vij, S. Kulkarni, K. Trinkaus, 2012, Blood.

Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia

Christopher A. Miller, M. O'Laughlin, L. Wartman, 2019, Haematologica.

Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

F. Gao, P. Westervelt, J. Dipersio, 2018, Leukemia research.

Limited sequence heterogeneity among biologically distinct human immunodeficiency virus type 1 isolates from individuals involved in a clustered infectious outbreak.

P. Westervelt, J. Garcia, L. Ratner, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Assessment of an Alternative Meropenem Dosing Strategy Compared with Imipenem‐Cilastatin or Traditional Meropenem Dosing After Cefepime Failure or Intolerance in Adults with Neutropenic Fever

P. Westervelt, E. Dubberke, R. Reichley, 2009, Pharmacotherapy.

plerixafor in relapsed or refractory acute myeloid leukemia A phase I/II study of chemosensitization with the CXCR4 antagonist

S. Kulkarni, K. Trinkaus, P. Westervelt, 2012 .

A phase 1 / 2 study of chemosensitization with the CXCR 4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

R. Vij, S. Kulkarni, K. Trinkaus, 2012 .

Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.

H. Rugo, G. Lyman, P. Westervelt, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.

J. Ritz, P. Westervelt, J. Dipersio, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow

Christopher A. Miller, J. Welch, R. Vij, 2018, Haematologica.

using plerixafor, an antagonist of the CXCR4/SDF-1 interaction Rapid mobilization of functional donor hematopoietic cells without G-CSF

R. Vij, P. Westervelt, D. Link, 2011 .

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.

R. Vij, P. Westervelt, D. Link, 2008, Blood.

Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice.

Christopher A. Miller, R. Wilson, R. Fulton, 2014, Blood.

A phase II study of 5‐day intravenous azacitidine in patients with myelodysplastic syndromes

R. Vij, P. Westervelt, J. Dipersio, 2009, American journal of hematology.

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

R. Vij, K. Trinkaus, P. Westervelt, 2001, Bone Marrow Transplantation.

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

P. Westervelt, J. Cortes, J. Guenot, 2018, Blood.

Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.

E. Leifer, H. Deeg, P. Westervelt, 2022, The Lancet. Haematology.

Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

R. Vij, K. Trinkaus, P. Westervelt, 2016, Haematologica.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

H. Deeg, R. Bejar, P. Greenberg, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Myeloid growth factors. Clinical practice guidelines in oncology.

J. Armitage, G. Demetri, G. Lyman, 2007, The Journal of the National Comprehensive Cancer Network.

Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML

R. Vij, P. Westervelt, J. Dipersio, 2014, International Journal of Hematology.

Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG

R. Vij, P. Westervelt, J. Dipersio, 2009, Bone Marrow Transplantation.

Genomic landscape of TP53-mutated myeloid malignancies

Christopher A. Miller, R. Fulton, T. Ley, 2023, medRxiv.

Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.

R. Vij, K. Trinkaus, P. Westervelt, 2017, Blood.

Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a low-dose (550 cGy) total body irradiation conditioning regimen.

R. Vij, K. Trinkaus, P. Westervelt, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants

H. Gendelman, P. Westervelt, J. Orenstein, 1992, Journal of virology.

Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

H. Gendelman, P. Westervelt, L. Ratner, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia

Erica K. Barnell, Zachary L. Skidmore, O. Griffith, 2021, JCO precision oncology.

Oral valganciclovir versus ganciclovir as delayed pre‐emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04‐0274) and review of the literature

R. Vij, K. Trinkaus, P. Westervelt, 2012, Transplant infectious disease : an official journal of the Transplantation Society.

Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide.

T. Ley, P. Westervelt, J. Dipersio, 2001, Blood.

Pathologic, Cytogenetic and Molecular Assessment of Acute Promyelocytic Leukemia Patients Treated with Arsenic Trioxide (As2O3)

J. Hess, P. Westervelt, Tao Zhang, 2000, Modern Pathology.

Use of Cytomegalovirus Intravenous Immune Globulin for the Adjunctive Treatment of Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients

P. Westervelt, E. Dubberke, R. Reichley, 2010, Pharmacotherapy.

Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.

R. Vij, P. Westervelt, J. Dipersio, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation.

F. Gao, P. Westervelt, J. Dipersio, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation

P. Westervelt, J. Dipersio, E. Dubberke, 2016, Transplant infectious disease : an official journal of the Transplantation Society.

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.

J. Wagner, P. Westervelt, J. Dipersio, 2018, Blood.

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.

F. Gao, P. Westervelt, J. Dipersio, 2021, Blood.

Adverse side-effects associated with G-CSF in patients with chronic myeloid leukemia undergoing allogeneic peripheral blood stem cell transplantation

R. Vij, K. Trinkaus, P. Westervelt, 2000, Bone Marrow Transplantation.

Myelodysplastic syndromes.

C. Bloomfield, M. Millenson, H. Deeg, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression

R. Wilson, R. Fulton, T. Ley, 2017, Cell.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Christopher A. Miller, R. Wilson, R. Fulton, 2016, The New England journal of medicine.

Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential

Christopher A. Miller, R. Fulton, T. Ley, 2018, Nature Communications.

Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context

Clement Adebamowo, Ritika Kundra, Steven J. M. Jones, 2018, Cell reports.

Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia

T. Ley, M. Walter, P. Westervelt, 2002, Proceedings of the National Academy of Sciences of the United States of America.

The Role of TP53 Mutations in the Origin and Evolution of Therapy-Related AML

Christopher A. Miller, R. Wilson, R. Fulton, 2014, Nature.

arising in the setting of severe congenital neutropenia Distinct patterns of mutations occurring in de novo AML versus AML

E. Mardis, C. Bloomfield, M. McLellan, 2013 .

Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.

R. Wilson, E. Mardis, M. Caligiuri, 2007, Blood.

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

O. Griffith, M. Griffith, D. Spencer, 2022, Science Translational Medicine.

Seed versus soil: the importance of the target cell for transgenic models of human leukemias.

T. Ley, P. Westervelt, 1999, Blood.

Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML

P. Westervelt, A. Ghobadi, M. Fiala, 2017, Case reports in hematology.

DNMT 3 A mutations in acute myeloid leukemia

Joshua F. McMichael, Cheryl F. Lichti, R. Wilson, 2016 .

Formation of noninfectious HIV-1 virus particles lacking a full-length envelope protein.

M. Becich, P. Westervelt, J. Garcia, 1991, AIDS research and human retroviruses.

Clonal diversity of recurrently mutated genes in myelodysplastic syndromes

E Mardis, R. Fulton, E. Mardis, 2013, Leukemia.

Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy

Christopher A. Miller, R. Wilson, R. Fulton, 2016, Leukemia.

Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.

Christopher A. Miller, R. Wilson, R. Fulton, 2016, Blood.

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

Christopher A. Miller, R. Wilson, R. Fulton, 2015, JAMA.

Comparative Evaluation of Single Fixed Dosing and Weight‐Based Dosing of Rasburicase for Tumor Lysis Syndrome

P. Westervelt, A. McBride, L. Boehmer, 2013, Pharmacotherapy.

Supplementary Materials Rationale for Selection an Aml Genome for Sequencing. We Selected a Specific Genome for Study Based on the following Criteria

Amy E. Hawkins, Brian H. Dunford-Shore, R. Wilson, 2022 .

Immune Escape of Relapsed AML Cells after Allogeneic Transplantation

Christopher A. Miller, R. Wilson, R. Fulton, 2018, The New England journal of medicine.

Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant.

Christopher A. Miller, R. Fulton, T. Ley, 2018, JCI insight.

TP 53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes

R. Fulton, T. Ley, J. Welch, 2016 .

Macrophage tropism determinants of human immunodeficiency virus type 1 in vivo

G. Shaw, P. Westervelt, B. Hahn, 1992, Journal of virology.

The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced‐intensity hematopoietic peripheral blood cell transplant – a retrospective study

F. Gao, P. Westervelt, J. Dipersio, 2020, Transplant international : official journal of the European Society for Organ Transplantation.

The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-Versus-Host Disparity Is Associated with Increased Acute Graft-Versus-Host Disease in Haploidentical Transplantation with Post-Transplant Cyclophosphamide.

F. Gao, P. Westervelt, J. Dipersio, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

F. Gao, P. Westervelt, J. Dipersio, 2018, Blood advances.

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review.

R. Vij, P. Westervelt, J. Dipersio, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML

R. Vij, P. Westervelt, J. Dipersio, 2016, Bone Marrow Transplantation.

HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation

P. Westervelt, J. Dipersio, T. Fehniger, 2016, Bone Marrow Transplantation.

Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.

R. Vij, K. Trinkaus, P. Westervelt, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential

Christopher A. Miller, R. Fulton, T. Ley, 2018, Nature Communications.

Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.

Christopher A. Miller, R. Fulton, D. Koboldt, 2015, Blood.

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia

R. Vij, K. Trinkaus, P. Westervelt, 2011 .

RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES

Li Ding, Kilannin Krysiak, David E. Larson, 2011, Nature Genetics.

High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression.

T. Ley, P. Westervelt, J. Dipersio, 2003, Blood.

Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers.

Christopher A. Miller, R. Fulton, T. Ley, 2021, The New England journal of medicine.

Structure—function relationships of the HIV‐1 envelope V3 loop tropism determinant: evidence for two distinct conformations

P. Westervelt, L. Ratner, C. Ebenbichler, 1993, AIDS.

Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study

F. Gao, J. Welch, R. Vij, 2011, American journal of hematology.

Comprehensive genomic analysis reveals FLT3 activation and a therapeutic strategy for a patient with relapsed adult B-lymphoblastic leukemia.

Benjamin J. Ainscough, Katie M. Campbell, James M. Eldred, 2016, Experimental hematology.

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

P. Westervelt, P. Fracasso, E. Zuhowski, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune hemolysis involving non-ABO/RhD alloantibodies following hematopoietic stem cell transplantation

P. Westervelt, L. Goodnough, J. DiPersio, 2001, Bone Marrow Transplantation.

Acquired copy number alterations in adult acute myeloid leukemia genomes

J. Kitzman, R. Wilson, R. Fulton, 2009, Proceedings of the National Academy of Sciences.

Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation

F. Gao, R. Vij, P. Westervelt, 2017, Bone Marrow Transplantation.

NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.

H. Rugo, G. Lyman, P. Westervelt, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning.

P. Westervelt, J. Dipersio, C. Abboud, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

J. Armitage, H. Rugo, G. Lyman, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.

B. Storer, P. Westervelt, F. Appelbaum, 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation.

K. Trinkaus, P. Westervelt, J. Dipersio, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes

F. Gao, R. Vij, P. Westervelt, 2014, Bone Marrow Transplantation.

Cardiomyopathy in patients after posttransplant cyclophosphamide–based hematopoietic cell transplantation

P. Westervelt, J. Dipersio, Chien-Jung Lin, 2017, Cancer.

Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation

R. Vij, P. Westervelt, J. Dipersio, 2014 .

Letermovir discontinuation at D+100 after Allogeneic Stem Cell Transplant is associated with increased CMV-related mortality.

F. Gao, R. Vij, P. Westervelt, 2022, Transplantation and cellular therapy.

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.

R. Vij, P. Westervelt, J. Dipersio, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

J. Ritz, P. Westervelt, J. Dipersio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of HIV-1 envelope V3 loop cleavage in cell tropism.

P. Westervelt, L. Ratner, R. Gu, 1993, AIDS research and human retroviruses.

Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

F. Gao, R. Vij, P. Westervelt, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myelodysplastic syndromes, version 2.2015.

C. Bloomfield, H. Deeg, R. Bejar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: late complications of therapy

R. Vij, P. Westervelt, D. Adkins, 2000, Bone Marrow Transplantation.

Response and toxicity associated with dose escalation of arsenic trioxide in the treatment of resistant acute promyelocytic leukemia

T. Ley, J. Haug, P. Westervelt, 1997 .

expression α very low levels of PML-RAR High-penetrance mouse model of acute promyelocytic leukemia with

T. Ley, P. Westervelt, J. Dipersio, 2013 .

Acquired, nonrandom chromosomal abnormalities associated with the development of acute promyelocytic leukemia in transgenic mice.

T. Ley, P. Westervelt, D. Zimonjic, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

E. Leifer, P. Westervelt, F. Appelbaum, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

E. Leifer, P. Westervelt, F. Appelbaum, 2020, Transplantation and Cellular Therapy.

Myeloid growth factors.

J. Armitage, M. Dwyer, H. Rugo, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia

T. Ley, M. Walter, J. Payton, 2022, Blood.

Phase 2 Study of MLN8237, An Investigational Aurora A Kinase (AAK) Inhibitor In Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS)

P. Westervelt, P. Fenaux, H. Fingert, 2010 .

Bone Marrow Biopsy Needle Type Affects Core Biopsy Specimen Length and Quality and Aspirate Hemodilution

Jonathan R. Brestoff, Abraham J. Qavi, P. Westervelt, 2018, American journal of clinical pathology.

result in an unstable predictive model. How highly corre- lated are these variables, and what might be the impact on generalizability?

T. Ley, J. Welch, P. Westervelt, 2016 .

A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001.

C. Bloomfield, R. Larson, S. Mandrekar, 2017, Blood advances.

Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G‐CSF

J. Welch, R. Vij, P. Westervelt, 2009, American journal of hematology.

Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802.

P. Westervelt, M. Pasquini, M. Horowitz, 2014, Blood.

Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.

F. Gao, R. Vij, P. Westervelt, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia.

R. Vij, P. Westervelt, J. Dipersio, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide results in outcomes similar to traditionally matched donors in active disease acute myeloid leukemia

R. Vij, P. Westervelt, J. Dipersio, 2017 .

A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma

R. Vij, P. Westervelt, M. Fiala, 2014, Bone Marrow Transplantation.

Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy

F. Gao, P. Westervelt, J. Dipersio, 2017, Bone Marrow Transplantation.

Role of Transplant Conditioning Regimen Intensity in High-Risk Acute Myelogenous Leukemia

P. Westervelt, 2020 .

Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial

J. Merker, M. Liedtke, P. Westervelt, 2018, Leukemia.

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.

Christopher A. Miller, R. Wilson, R. Fulton, 2017, Blood.

A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML

J. Welch, R. Vij, P. Westervelt, 2013, American journal of hematology.

Allogeneic hematopoietic cell transplantation in morphologic leukemia‐free aplastic state

P. Westervelt, J. Dipersio, Kiran R. Vij, 2017, American journal of hematology.

Myeloid growth factors.

J. Armitage, G. Demetri, G. Lyman, 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma.

R. Vij, P. Westervelt, J. Dipersio, 2016, Clinical lymphoma, myeloma & leukemia.

Acute myeloid leukemia presenting with extensive bone marrow necrosis, leukemia cutis and testicular involvement: successful treatment with allogeneic hematopoietic stem cell transplantation

P. Westervelt, J. Dipersio, R. Romee, 2016, Bone Marrow Transplantation.

Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes

F. Gao, R. Vij, P. Westervelt, 2015 .

The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis.

F. Gao, P. Westervelt, J. Dipersio, 2022, Blood.

A common founding clone with TP53 and PTEN mutations gives rise to a concurrent germ cell tumor and acute megakaryoblastic leukemia

Christopher A. Miller, O. Griffith, B. Ozenberger, 2016, Cold Spring Harbor molecular case studies.

Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001)

C. Bloomfield, J. Byrd, R. Larson, 2015 .

Exome analysis of treatment‐related AML after APL suggests secondary evolution

Christopher A. Miller, J. Welch, S. Heath, 2018, British journal of haematology.

M. Walter, P. Westervelt, J. Dipersio, 2021, Blood.

Mouse models of acute promyelocytic leukemia

T. Ley, M. Walter, P. Westervelt, 2001, Current opinion in hematology.

Genetic and Transcriptional Contributions to Relapse in Normal Karyotype Acute Myeloid Leukemia

Christopher A. Miller, R. Fulton, T. Ley, 2021, Blood cancer discovery.

Silybum marianum (milk thistle) in the management and prevention of hepatotoxicity in a patient undergoing reinduction therapy for acute myelogenous leukemia

P. Westervelt, A. McBride, K. Augustin, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Factors Associated With Clinical Deterioration Among Patients Hospitalized on the Wards at a Tertiary Cancer Hospital.

B. Gage, M. Kollef, P. Westervelt, 2019, Journal of oncology practice.

A Multi-Center, Randomized, Double Blind, Phase III Clinical Trial Comparing Steroids/Placebo Vs. Steroids/Mycophenolate Mofetil As Initial Therapy for Acute Graft-Versus-Host Disease. Blood and Marrow Transplant Clinical Trials Network Study 0802

P. Westervelt, M. Pasquini, M. Horowitz, 2013 .

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

F. Gao, M. Walter, R. Vij, 2022, Blood.

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

F. Gao, P. Westervelt, J. Dipersio, 2021, Blood.

Subclonal Evolution Characterizes MDS Disease Progression Following Allogeneic Stem Cell Transplant

Christopher A. Miller, R. Fulton, T. Ley, 2017 .

A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.

R. Vij, S. Kulkarni, P. Westervelt, 2009 .

Mutation Clearance after Transplantation for Myelodysplastic Syndrome

R. Fulton, T. Ley, J. Welch, 2018, The New England journal of medicine.

Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product

Stephen M. Shaw, P. Westervelt, J. Dipersio, 2018, Blood.

Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.

R. Vij, S. Kulkarni, P. Westervelt, 2008 .

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

M. Dhodapkar, P. Westervelt, M. Perales, 2023, eClinicalMedicine.

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

P. Westervelt, J. Dipersio, H. Kantarjian, 2018, Blood.

A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia

R. Vij, L. Wartman, P. Westervelt, 2014, Leukemia & lymphoma.

High Dose Sargramostim (GM-CSF) Combined with IV Plerixafor for the Mobilization of Peripheral Blood Stem Cells (PBSC) From Normal HLA-Matched Allogeneic Sibling Donors Results in Hypercoagulability

K. Trinkaus, P. Westervelt, J. Dipersio, 2012 .

NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.

Elizabeth M. Hollinger, Shannon R. McCurdy, H. Deeg, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

HIV-1 V3 envelope sequences required for macrophage infection.

P. Westervelt, L. Ratner, T. Henkel, 1995, AIDS.

Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells

Christopher A. Miller, R. Fulton, T. Ley, 2021, Leukemia.

Genomic landscape of TP53-mutated myeloid malignancies

R. Fulton, T. Ley, M. Walter, 2023, Blood advances.

A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

J. Ritz, P. Westervelt, J. Dipersio, 2016 .

Genome-wide analysis of focal DNA hypermethylation in IDH-mutant AML samples

Christopher A. Miller, R. Fulton, T. Ley, 2021, bioRxiv.

A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,

R. Vij, P. Westervelt, J. Dipersio, 2011 .

Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy.

T. Ley, M. Walter, R. Vij, 2007 .

Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

P. Riedell, R. Vij, P. Westervelt, 2017 .

Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma

P. Westervelt, J. Dipersio, N. Bartlett, 2020 .

Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Phase I-II Trial of Early Azacitidine after Matched Unrelated Donor Hematopoietic Cell Transplant.

M. Walter, R. Vij, P. Westervelt, 2023, Transplantation and cellular therapy.

IFNL4 and donor selection for matched unrelated donor haematopoietic stem-cell transplantation

P. Westervelt, 2020, The Lancet Haematology.

The Activity and Toxicity of Dasatinib in Relapsed or Plateau-Phase Multiple Myeloma.

F. Gao, R. Vij, P. Westervelt, 2007 .

A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

R. Vij, K. Trinkaus, P. Westervelt, 2011, Blood.

Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.

R. Vij, P. Westervelt, D. Link, 2008, Blood.

Strengthening implementation guidelines for HIV service delivery: Considerations for future evidence generation and synthesis

Najam Ali Khan, R. Fulton, T. Ley, 2023, PLoS medicine.

HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

F. Gao, P. Westervelt, J. Dipersio, 2018, Blood advances.

A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML

J. Welch, R. Vij, P. Westervelt, 2013, American journal of hematology.

Peripheral-blood stem cells versus bone marrow from unrelated donors.

P. Westervelt, S. Mineishi, D. Porter, 2012, The New England journal of medicine.

Clinician Perspectives on Barriers and Enablers to Implementing an Inpatient Oncology Early Warning System: A Mixed-Methods Study.

R. Govindan, M. Kollef, P. Westervelt, 2023, JCO Clinical Cancer Informatics.

Clinical Trials and Observations

Chieh-Yu Liu, K. Trinkaus, P. Westervelt, 2022 .

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

Christopher A. Miller, R. Fulton, E. Mardis, 2015, JAMA.

Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow

Christopher A. Miller, J. Welch, R. Vij, 2018, Haematologica.

Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome.

R. Vij, P. Westervelt, J. Dipersio, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

R. Vij, P. Westervelt, J. Dipersio, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Allogeneic Hematopoietic Stem Cell Transplant Versus No Transplant in Adult Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in First Complete Remission and Complete Molecular Remission

F. Gao, P. Westervelt, J. Dipersio, 2020 .

Blinatumomab consolidation post-autologous stem cell Blinatumomab consolidation post-autologous stem cell transplantation in patients with diffuse large B-cell lymphoma transplantation in patients with diffuse large B-cell lymphoma

P. Westervelt, J. Dipersio, Julie K. Ritchey, 2022 .

Itacitinib for Prevention of Graft-Versus-Host Disease and Cytokine Release Syndrome with T-Cell Replete Peripheral Blood Haploidentical Transplantation

P. Westervelt, J. Dipersio, Julie K. Ritchey, 2023, Blood.

Fresh or Cryopreserved CD34+-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation.

F. Gao, P. Westervelt, J. Dipersio, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ruxolitinib for steroid‐refractory acute graft‐versus‐host disease

P. Westervelt, J. Dipersio, M. Fiala, 2019, Transplant international : official journal of the European Society for Organ Transplantation.

Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102

L. Steuten, P. Westervelt, J. Pidala, 2024, JCO oncology practice.

Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.

Christopher A. Miller, Matthew J. Schuelke, R. Fulton, 2022, Blood cancer discovery.

Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.

Christopher A. Miller, R. Fulton, E. Mardis, 2016, Blood.

MYELOID NEOPLASIA Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML

E. Mardis, T. Ley, M. Walter, 2016 .

MYELOID NEOPLASIA Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML

E. Mardis, T. Ley, M. Walter, 2016 .